01—Abstract
Summary
Summary of the 10-Q filed October 28, 2026. Cited figures are marked; the original filing is the authoritative source.
IDEX Corporation's Form 10-Q for the quarter ended September 30, 2026 reports third-quarter net sales of $951.7 milliona, up 8% on both a reported and organic basis versus $878.7 million a year earlier.
Reported diluted EPS attributable to IDEX was $1.95b, up 15% from $1.70, and adjusted diluted EPS was $2.33, up 15% from $2.03. Operating income rose to $208.0 million from $185.8 million, and gross margin was 45.1% versus 44.5%. For the nine months, net sales were $2,759.2 million, up 8%, and diluted EPS was $5.49 versus $4.70, with the company noting that IEEPA tariff refunds contributed $0.10 to nine-month diluted EPS.
Growth was led by the Health & Science Technologies segment, where Q3 net sales rose 14% and Adjusted EBITDA rose 18%, driven by AI-related demand for data center power and semiconductor markets, as well as space and defense. Fluid & Metering Technologies sales rose 3% and Fire & Safety/Diversified Products sales rose 5% in the quarter. Operating cash flow for the nine months was $543.2 millionc, and free cash flow was $477.3 million, compared with $427.0 million a year earlier.
The company repurchased $227.0 milliond of shares in the nine months and paid $160.7 million in dividends. Balance sheet and liquidity remain solid. Cash and cash equivalents were $602.1 million, total borrowings were $1,759.0 million, and the company entered a second amended and restated $800 million revolving credit agreement maturing September 2031.
The company stated it was in compliance with its covenants, with a leverage ratio of 1.72 to 1 and an interest coverage ratio of 14.69 to 1. Fitch affirmed its BBB+ rating in September 2026.
02—Key points
Key Highlights
- Q3 2026 net sales of $951.7 million, up 8% reported and organically, versus $878.7 million in Q3 2025.
- Q3 reported diluted EPS of $1.95 (up 15%) and adjusted diluted EPS of $2.33 (up 15%).
- Health & Science Technologies Q3 net sales rose 14% and Adjusted EBITDA rose 18%, driven by AI-related data center and semiconductor demand plus space and defense.
- Nine-month operating cash flow of $543.2 million and free cash flow of $477.3 million, up from $470.9 million and $427.0 million.
- IEEPA tariff refunds benefited nine-month results, contributing $0.10 to diluted EPS, with the company collecting substantially all anticipated refunds in Q2 2026.
- Shareholder returns in Q3 included $74.6 million of share repurchases and $54.0 million of dividends; $699.7 million of repurchase authorization remained at September 30, 2026.
- Entered a new $800 million revolving credit agreement maturing September 2031; leverage ratio 1.72 to 1 and interest coverage 14.69 to 1 for covenant purposes.
03—One dollar
Follow one dollar
Of each $1.00 of revenue in Q3 FY2026, Idex kept $0.15.
- Revenue$951.7M100.0%
- Cost of revenue−$522.2M54.9%
- Gross profit$429.5M45.1%
- Operating costs−$221.5M23.3%
- Operating income$208.0M21.9%
- Interest, other & tax−$63.9M6.7%
- Net income$144.1M15.1%
04—Financials
Financial Highlights
Figures from 10-QQ3 FY2026filed October 28, 2026Financial Statements
Q3 FY2026 against Q3 FY2025
| Line item | Q3 FY2026Q3 FY2025 | Change |
|---|---|---|
| Revenue | $951.70M$878.70M | +8.3% |
| Cost of Revenue | $522.20M$488.10M | +7.0% |
| Gross Profit | $429.50M$390.60M | +10.0% |
| SG&A Expenses | $218.10M$204.70M | +6.5% |
| Operating Income | $208.00M$185.80M | +11.9% |
| Net Income | $144.10M$127.80M | +12.8% |
| EPS (Basic) | $1.95$1.70 | +14.7% |
| EPS (Diluted) | $1.95$1.70 | +14.7% |
| Shares Outstanding (Basic) | 73.70M75.10M | −1.9% |
| Shares Outstanding (Diluted) | 74.00M75.20M | −1.6% |
05—Questions
Frequently Asked Questions
How did IDEX perform in the third quarter of 2026?
Net sales were $951.7 million, up 8% on both reported and organic bases. Operating income was $208.0 million versus $185.8 million a year earlier, and reported diluted EPS was $1.95 versus $1.70, an increase of 15%.
Which segment drove growth?
Health & Science Technologies led growth, with Q3 net sales up 14% and Adjusted EBITDA up 18%. The filing attributes this to higher volumes from AI-driven demand for data center power and semiconductor markets, along with strength in space and defense. Fluid & Metering Technologies net sales rose 3%, and Fire & Safety/Diversified Products rose 5%.
What impact did the IEEPA tariff refunds have?
After the U.S. Supreme Court invalidated IEEPA tariffs in February 2026, the company collected substantially all anticipated refunds in Q2 2026. For the nine months, the refunds included a $22.7 million reduction in Cost of sales and a $13.1 million reduction in Net sales from expected customer rebates, contributing $0.10 to diluted EPS. The filing notes that new tariffs were implemented under alternative authority, but the tariffs enacted in 2025 and Q1 2026 did not have a material impact.
How is the company returning capital and managing its balance sheet?
In the nine months ended September 30, 2026, the company repurchased shares for $227.0 million and paid $160.7 million in dividends. Cash and cash equivalents were $602.1 million, and total borrowings were $1,759.0 million. Revolving Facility availability was $637.7 million at quarter-end.
Are there any notable restructuring or other items?
The company recorded restructuring expenses and asset impairments of $3.4 million in Q3 2026, primarily severance linked to the anticipated closure of a Health & Science Technologies facility. Nine-month results also included $4.8 million of asset impairments in Fluid & Metering Technologies. Legal settlement funds received, net of costs, contributed $3.0 million to nine-month pre-tax income.
06—Continue